A post-authorization, multicenter, non- interventional, safety study using HSA-free scIFNβ-1a in patients with multiple sclerosis.

Trial Profile

A post-authorization, multicenter, non- interventional, safety study using HSA-free scIFNβ-1a in patients with multiple sclerosis.

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Nov 2016

At a glance

  • Drugs Interferon beta-1a (Primary)
  • Indications Multiple sclerosis
  • Focus Adverse reactions
  • Acronyms STEP
  • Most Recent Events

    • 12 Nov 2016 New trial record
    • 17 Sep 2016 Results presented at the 32nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top